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Abstract
Although cognitive difficulties are not frequently reported by patients among
the initial symptoms of Multiple Sclerosis (MS), there is sufficient evidence that
cognitive impairment is present from the early stage of the disease. Today it is
commonly accepted that roughly one-half of individuals with MS will experience
cognitive dysfunction over the course of the disease. Though MS was originally
considered a disease of white matter, more recent investigations with advanced
immunohistochemistry techniques have revealed that demyelination of gray matter
is a common neuropathological feature in MS contributing significantly to cognitive
impairment. However, despite now been recognized as a core symptom of MS,
evidence up till now is only modest regarding the efficacy of pharmacological
agents on cognitive dysfunction and non-pharmacological interventions such as
cognitive rehabilitation also provide incomplete evidence on whether they might
improve or stabilize cognitive impairment and especially over long follow up
periods. Despite this general consensus, there are studies that have reported the
efficacy of cognitive neurorehabilitation in reducing MS associated cognitive defi-
cits. In this chapter we provide a selective review of the most relevant features
related to this topic.
Keywords: multiple sclerosis, neuropsychological functions, cognition,
cognitive neurorehabilitation
1. Introduction
Historically the disease today known as multiple sclerosis (MS) has been
referred to in the historical medical literature with a variety of terms, including,
disseminated sclerosis and sclerose en plaque [1]. Lidwina van Schiedam, was the
first potential case of MS dating as far back as 1421, when Jan van Berieren
commented on her illness. Records showed that she had difficulties walking,
paralysis of the right arm, decreased sensation and visual difficulties [2].
Today we know that MS is a chronic inflammatory autoimmune degenerative
disease of the central nervous system (CNS). It is the most common non-traumatic
neurological disorder among young adults leading to disability. The etiology of
MS involves white matter pathology, cortical atrophy, cortical lesions, and micro-
structural abnormalities in deep gray matter that impact structural and functional
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connectivity [3]. Cognitive impairment in MS appears to be a result of this diffuse
disruption in brain networks [4]. These patients may also present sensorimotor [5],
visual [6], bladder, cerebellar [7] and emotional difficulties leading to functional
disability [8] and poorer quality of life [9].
Environmental factors and especially geographical latitude may significantly
influence the development of MS. However, genetic susceptibility as is evident
from twin studies and familial cases, suggests that MS disease causality is due to a
complex interaction between multiple genes and environmental factors, eventually
leading to inflammatory-mediated central nervous system deterioration [10].
Genomic studies, with specific HLA antigens (HLA-DR2), have confirmed the
genetic susceptibility of MS [10]. Numerous other environmental factors have been
evaluated that may be associated with MS, but methodological caveats have casted
doubts on their validity. On average, MS patients contracted common childhood
illnesses at later ages than healthy controls [11]. A biomarker of Epstein-Barr virus
(anti-EBNA IgG seropositivity), infectious mononucleosis, and smoking have
shown the strongest consistent evidence of an association. However, additional data
and better-designed studies are needed to establish robust evidence [12].
MS disease course is heterogeneous in nature and several types have been
described: Relapsing remitting MS (RRMS), Active (with relapses and/or new
lesions on MRI), Not Active (no relapses or MRI activity), Progressive MS (Sec-
ondary Progressive MS (SPMS) and Primary Progressive MS (PPMS), Active with
Progression (relapses/MRI activity and clinical deterioration not due to relapses),
Active but without Progression (relapses but no clinical deterioration), Not Active
but with Progression, Not Active and without Progression (stable disease) [13]. The
use of these terms is primarily for descriptive purposes and for setting reasonable
expectations for treatment.
This chapter is not a comprehensive review of the extensive literature on neu-
ropsychological functions and cognitive rehabilitation in multiple sclerosis, but
rather a selective review of the most relevant features related to this topic.
2. Neuropsychological functions in multiple sclerosis
Dating back to the seminal writings on MS, Charcot’s observations of the adverse
effects that MS exerts on memory, concept formation, and the intellect [14], were
underestimated for many decades in the neurology literature. It was only with the
emergence of the comprehensive care model in the early 1980s, that the nature and
significance of cognitive dysfunction in MS became appreciated. The medical com-
munity, due to the often-subtle nature of cognitive deficits in MS, and the difficulty
in detecting these deficits during routine clinical practice, was initially slow to
appreciate them as a core clinical symptom of MS. Instead, they believed that
cognitive impairment was a relatively rare entity in MS, occurred only in advanced
cases with a high level of physical disability and was associated with subcortical
dementia [15].
Cognitive difficulties are not frequently reported by patients among the initial
symptoms of MS, although there is sufficient evidence that cognitive impairment is
present from the early stage of the disease (see for e.g., the study by [16], which
assessed MS patients neuropsychologically, not more than 2 years after experienc-
ing their first neurological symptoms, and [17], who presents three cases evaluated
at different stages of the disease). Moreover, cognitive impairment may be present
in the early stages of the disease in patients with relatively low or mild physical
disability (see for e.g. the studies by [18, 19] who found cognitive deficits in
patients with an EDSS disability score of ≤3.5, that had not yet been influenced
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significantly in their daily functional abilities and employment status). A recent
anatomofunctional study utilizing diffusion imaging and resting state functional
MRI, revealed that disconnection in the default mode network (DMN) and atten-
tional networks (ATT), may deprive the brain of the necessary compensatory
mechanisms required to face the widespread structural damage during the early
course of MS, providing a possible explanation for the cognitive dysfunction in
these early stages of the disease [20].
Although it is now commonly accepted that roughly one-half of individuals with
MS [21, 22], will experience clinical deficits over the course of the disease, preva-
lence rates are highly variable and depend to a large extent on the type of MS
population studied, the clinical, demographic and sociodemographic characteristics
and the year conducted. A recent study that included RRMS and SPMS patients
attending an outpatient neurology clinic reported an overall cognitive dysfunction
prevalence rate of 53.7% [23]. Moreover, the study by [22], reported that 47% of
their MS patients recruited from an outpatient clinical setting, diagnosed with the
revised McDonald criteria [24], the majority with RRMS and mean duration of
illness at 9.6 years, assessed with a brief cognitive measure (BICAMS), performed
below the 1SD cutoff set for impairment on at least one of the three tests that
comprise this brief neuropsychological battery. In an interesting cross-sectional
study that evaluated the patterns of cognitive impairment in patients with disease
duration of up to 30 years, 20.9% performed below the 1SD cutoff for impairment
by the 5th year from disease onset, by 10 years this had reached 29.3%. By utilizing
regression modeling the authors suggested that cognitive impairment may precede
MS onset by 1.2 years [25].
Most of the evidence suggests that cognitive impairment in MS patients is
present during all disease stages and across all disease clinical subtypes [26–28],
including, RRMS, PPMS, SPMS, Clinically Isolated Syndrome (CIS) and “benign
MS” [29, 30], and even Radiologically Isolated Syndrome—(RIS) [31]. Based on the
majority of studies that have compared cognitive functions across disease subtype,
deficits appear to be more frequent and more widespread in the progressive type
rather than in the relapsing form of the disease [23, 29, 31–32].
The dissemination of lesions in cerebral white matter including their affinity for
periventricular regions provides the basis for some cognitive dysfunction common-
alities [33]. In this respect, some cognitive domains appear to be more commonly
compromised than others. Information processing efficiency, episodic memory,
attention, and executive functioning are the domains found predominantly to be
detrimentally affected in MS [21, 34, 35]. Among these domains the most common
pattern involves circumscribed deficits as a combination of one or two of the above-
mentioned domains (e.g., attention/processing speed, learning/memory, and or
executive functions [11, 15, 21].
Symptoms like cognitive and physical fatigue, which are often accompanied by
depression and anxiety, may negatively influence cognition in MS patients. This is
especially true when extended periods are required to complete and appear more
relevant for the patient’s daily life than what may be assumed by many physicians
treating MS patients [11].
Although cognitive impairment is highly prevalent among MS patients, some
have a tendency to withstand severe disease burden (e.g., white matter lesions and
cerebral atrophy), and present with overall lower levels of cognitive decline. One
possible explanation for this protective mechanism is the brain reserve hypothesis
and the cognitive reserve theory [36]. Recently, it has been verified that highly
significant protection for cognitive impairment is provided by brain reserve,
defined as the maximal lifetime brain growth (MLBG), and estimated with intra-
cranial volume or head circumference. Larger MLBG a proxy for neuronal and
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synaptic count has been linked to lower risk for cognitive impairment in MS [37].
This larger MLBG appears to be associated with more robust neural networks
resistant to disease-related disruption and also provides more potential degrees of
freedom for the brain to plastically reorganize in the face of MS disease related
challenges.
2.1 Assessment of neuropsychological functions in MS
The multidimensional nature of cognitive dysfunction in MS necessitates an
assessment of numerous cognitive domains. The challenge until recently was to
find the optimal combination of cognitive tests that would provide an accurate
picture of the deficits whilst avoiding the use of unnecessary and time-consuming
measures [15].
In order to overcome some of the limitations in assessing cognition in MS, and
considering the fact that not all neuropsychological measures are appropriate for
the MS population, a number of neuropsychological assessment tools (brief
screening batteries and comprehensive neuropsychological batteries), have been
utilized specifically for this population in routine clinical care and for research
purposes. Table 1 provides a summary of the most important neuropsychological
tools utilized in MS patients.
2.2 Neuropsychological functions and neuroimaging
Although MS was originally considered to be a disease of White Matter (WM),
more recently with the development and utilization of advanced immunohisto-
chemistry techniques investigators have begun to appreciate that demyelination
of gray matter (GM) is a common neuropathological feature in MS patients.
Demyelination of GM appears to be more common in the cerebellum, spinal cord
and hippocampus. Essentially, however, no areas within the CNS are actually
spared [38]. The thalamus is considered the most frequently affected subcortical
Cognitive
domain
Rao brief repeatable
neuropsychological
battery (BRB)
Minimal assessment of
cognitive function in
MS (MACFIMS)
NINDS
common
data elements
Brief assessment of
multiple
sclerosis (BICAMS)
Cognitive
processing
speed
SDMT SDMT SDMT SDMT
PASAT PASAT PASAT —
Language COWAT COWAT COWAT —
Visual/
spatial
— JLO — —
Memory SRT CVLT2 CVLT2 CVLT2
10/36 Spatial Recall
Test
BVMTR BVMTR BVMTR
Executive
function
— D-KEFS D-KEFS —
SDMT: Symbol Digits Modalities Test; PASAT: Paced Auditory Serial Addition Test; COWAT: Controlled Oral
Word Association Test; CVLT2: California Verbal Learning Test 2nd edition; BVMTR: Brief Visuospatial Memory
Test Revised; DKEFS: Delis Kaplan Executive Function System Sorting Test.
Table 1.
Neuropsychological batteries utilized in MS patients.
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GM structure, but lesions have been identified within the putamen, pallidum,
caudate, amygdale, substantia nigra and hypothalamus [39].
Considering the above, clinicians and researchers investigating neuropsycholog-
ical functions in MS patients have realized that cognitive dysfunction in this
population cannot be explained by WM pathology alone. GM pathology appears to
have a significant impact on cognitive impairment, but requires novel neuroimag-
ing technology in order to detect and visualize these types of lesions. Due to these
visualization difficulties in current imaging technologies, research in MS has shifted
its focus primarily to comparing WM and GM measures of atrophy [39]. In this
respect, [40], noted a similar increase in WM atrophy across disease stages (three-
fold), whereas, atrophy of the GM increased proportionally according to disease
stage, i.e. three-fold in CIS converting to RRMS, versus 14-fold in SPMS patients.
Another important issue is that GM atrophy has been reported to be regionally
specific, involving early volume loss of the basal ganglia, corpus callosum and
thalamus. Recent studies have outlined the significance of thalamic volume in
relation to cognitive impairment. One such report by [41] found lower thalamic
volumes in MS patients compared to healthy participants, with the lowest volumes
found in severely cognitive impaired patients. In one of our recent studies, we
provide evidence that thalamic atrophy was the best predictor of cognitive dys-
function in RRMS patients and was also highly associated with activities of daily
living and employment status [42]. Moreover, in a similar study that recruited late
stage SPMS patients, we found that corpus callosum atrophy was associated with
deficits in cognitive flexibility, processing speed, episodic memory, executive func-
tions, reaction time and phonological verbal fluency. Processing speed and com-
posite memory were the most sensitive markers for predicting employment status.
Corpus callosum atrophy was the most sensitive MRI marker for episodic memory
and processing speed deficits. Moreover, corpus callosum atrophy predicted a clin-
ically meaningful cognitive decline, affecting employment status in our SPMS
patients [43]. Thus, it appears that irreversible tissue loss, as measured by brain
atrophy of the white and gray matter, is strongly associated to cognitive function in
the MS population. While white matter atrophy has also been reported to contribute
significantly to impairment in mental processing speed and working memory,
gray matter atrophy was highly predictive for verbal memory status, but addition-
ally predicted neuropsychiatric symptoms such as disinhibition and euphoria [44].
3. Interventions for cognitive dysfunction in multiple sclerosis
Recent evidence from empirical research has indicated that cognitive dysfunc-
tion in MS patients is highly related to everyday functioning abilities [45]. One
such study that evaluated associations between cognitive functions and objective
performance on measures of everyday functioning in MS, [46], reported that MS
patients had significantly more difficulties in simple and more complex cooking
abilities, using the phone, taking medication, and paying the bills, compared to
healthy participants. An interesting study by O’Brien et al. [47] and a more ecolog-
ically valid study by Goverover et al [48], utilizing an actual reality (AR) approach
through the use of everyday tasks requiring the internet (e.g. booking an airline
ticket, purchasing cookies and ordering pizza), the authors report significant cor-
relations between these tasks and performance on mental processing speed
(SDMT), concluding that this measure contributes significantly to predicting
everyday functioning capacity in MS. A more recent study, [48], examined the
ability of MS patients to manage their finances. The authors found that MS patients
demonstrated and reported more difficulties in managing their finances compared
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to healthy controls. Moreover, MS patient’s difficulties in handling their finances
were associated with the severity of cognitive dysfunction. As this important every-
day task requires intact mental processing ability and executive-attentional abilities,
domains usually impaired in MS individuals, these findings may serve as potential
intervention indicators when planning cognitive rehabilitation interventions.
From the findings reported by the studies mentioned previously, it becomes
obvious that interventions to alleviate, stabilize, reduce or compensate for cognitive
impairment are of an extremely high priority, in order to provide MS individuals
with the necessary mechanisms to better handle their everyday functioning disabil-
ities. The evidence up till now is only modest regarding the efficacy of pharmaco-
logical agents on cognitive dysfunction [49, 50], and non-pharmacological
interventions such as cognitive rehabilitation also provide incomplete evidence on
whether they might improve or stabilize cognitive impairment and especially over
long follow up periods [51]. Despite this general consensus, there are studies that
have reported the efficacy of pharmacological agents [52] and cognitive rehabilita-
tion [28, 53, 54] in reducing MS associated cognitive deficits.
3.1 Cognitive neurorehabilitation in multiple sclerosis
The goals of non-pharmacological treatments for MS-related cognitive deficits
are similar to those of the immune-modulating drugs. In other words, these inter-
ventions are used with the intent of preventing the progression of cognitive dys-
function and promoting a therapeutic ‘milieu’ in which optimal cognitive
functioning can occur, and include specific approaches which are known to be
effective in remediating cognitive disorders of any etiology [15]. Cognitive rehabil-
itation or ‘rehabilitation of individuals with cognitive impairment’ [55] include
specific approaches designed to assist the MS patient to better cope with existing
cognitive impairments or to improve a specific cognitive skill. It focuses on two
main approaches: the restorative or functional training approach (i.e. ameliorating
patients’ deficits in processing and interpreting information—e.g. when cognitive
training is used to enhance attention or memory performance). The restorative
approach depends on the brains capability of cortical reorganization following
injury (i.e. that the brain possesses some degree of plasticity). The second is the
compensatory or strategy training approach (e.g. modifying the patient’s environ-
ment, using a calendar and set phone reminders). These approaches have different
goals and limitations, and may be used in isolation or in combination. For example,
in patients with extensive tissue loss, neural plasticity might be hampered and no
or little effect will result from restorative or functional training. In that particular
patient, compensatory or strategy training might help the patient to work around
the problems that are present. As for most MS patients, especially those with a
relapsing disease course, it is expected that restorative or functional training will
lead to improved cognitive functioning on neuropsychological measures, improved
functioning in everyday life activities, and ultimately will lead to an improvement
in network efficiency [56].
Several studies have investigated the effectiveness of cognitive rehabilitation
interventions in patients with MS, including computer-based training and neuro-
psychological counseling, but with inconsistent results. The majority of studies
found improvements in specific cognitive domains, but the evidence provided in
the literature remains inconclusive [57]. A significant limitation in providing evi-
dence on the efficacy of studies involving cognitive rehabilitation is the great
variability in the methods or strategies utilized for treatment, the measures used to
assess cognition and other secondary outcome variables and the lack of ecologically
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valid outcome measures in order to assess the efficiency of these interventions
in everyday functioning ability.
Applying a technique known as the Story Memory Technique (SMT), [58]
provided class 1 evidence that this technique applied for 5 weeks/twice weekly
(10 sessions) with an emphasis on teaching context and imagery to facilitate learn-
ing, improved episodic memory in MS patients relative to controls and moreover
produced increased f-MRI activation during a memory task in frontal and parietal
regions. Positive effects were additionally observed for objective measures of
everyday memory function, general contentment, and executive functioning. These
positive outcomes were sustained for a period of 6 months.
Clinical trials utilizing the RehaCom computerized software in MS patients with
cognitive impairments have also shown positive outcomes. Bonavita et al. [59],
noted significant pre-to post treatment improvements in a RehaCom treated MS
cohort, on mental information processing, executive functions and attention. This
and other similar studies have reported positive outcomes in MS patients treated
with this software, and moreover, associations between functional neuroimaging
(f-MRI) findings with changes in neurocognitive measures have been reported
[59–61]. In a multicenter Italian study, RehaCom was utilized to provide specific
intensive cognitive training for 12 months. Results showed that MS patients treated
with this modality had improved scores post treatment on the SDMT, PASAT, and
episodic memory measures relative to MS patients who received aspecific psycho-
logical therapy for the same period of time [62].
In 2017, our group, [53], conducted a multicenter randomized controlled trial
with 58 clinically stable RRMS patients utilizing computer-assisted (RehaCom)
functional cognitive training with an emphasis on episodic memory, information
processing speed/attention, and executive functions for 10 weeks. Our findings
revealed that only the group that had received functional cognitive training showed
significant improvements in verbal and visuospatial episodic memory, processing
speed/attention, and executive functioning from pre—to postassessment. More-
over, the improvement obtained on attention was retained over 6 months providing
evidence on the long term benefits of this intervention. Treated patients rated the
intervention positively and were more confident about their cognitive abilities
following treatment.
While the previously mentioned positive results regarding the efficacy of cogni-
tive rehabilitation interventions in MS individuals cannot be overstated, it is
important to note that a recently published Cochrane Review that included 15
studies and 989 MS participants regarding the efficacy of memory retraining tech-
niques with or without the assistance of computer software, concluded that there
is only limited evidence on the effectiveness of memory rehabilitation in this popu-
lation. The authors further suggest that more RCTs of high methodological quality
be conducted with the utilization of ecologically valid outcome assessments [63].
Another Cochrane Review that included 20 studies and 966 MS participants
evaluating the effectiveness of neuropsychological rehabilitation in MS [64],
reported low-level evidence for the positive effects of neuropsychological rehabili-
tation in this population. However, the authors reported that the comparability of
the 20 studies reviewed was limited due to heterogeneity of interventions and
outcome measures. It should be noted however, that the majority of studies
included in this review did show some evidence of positive effects on cognitive
outcome measures.
Despite the limitations noted by the previously mentioned Cochrane reviews,
a growing body of literature supports the efficacy of cognitive rehabilitation for
individuals with MS and more randomized controlled trials are needed to support
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existing and new rehabilitation techniques. Cognitive rehabilitation appears to be
useful for all patients with MS regardless of disease course and level of cognitive
impairment, although studies including exclusively MS patients with progressive
disease course are limited. Future clinical trials utilizing cognitive rehabilitation
interventions in progressive MS patients should become a priority.
4. Conclusions
Cognitive impairment is frequently encountered in MS individuals, irrespective
of disease duration, severity of physical disability, and at both the earlier and later
disease stages. Moreover, cognitive dysfunction in this population may have a
significant negative impact on quality of life, activities of daily living and employ-
ment status. Furthermore, past and current pharmacological treatments have
shown inconsistent findings in alleviating cognitive impairment in individuals with
MS requiring further clarification. This inconsistency regarding the effects of
pharmacological interventions on cognition, coupled with the reduced ability to
effectively handle everyday tasks, loss of employment and social interaction
capacity, prioritizes the need for utilizing potentially more effective
non-pharmacological, neurobehavioral interventions to address cognitive dysfunc-
tion and everyday functioning abilities. Neurobehavioral interventions utilizing
cognitive rehabilitation have shown favorable effects on MS patients cognitive
performance and other related skills, and in some cases, have managed to generalize
these positive effects to MS individual’s everyday life functioning ability. In this
respect it becomes obvious that there is a need for rigorous new cognitive
neurorehabilitation studies that may overcome some of the methodological limita-
tions of older studies, and provide robust evidence regarding the efficiency of such
cognitive interventions for the MS population.
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